Hormonal therapies involving growth hormone (GH) and IGF-1 are also investigated for their anabolic effects, although they are not currently employed in clinical practice due to significant safety concerns, including the risk of cancer, diabetes, and other adverse effects, particularly in older adults [159]. This evidence concerns the gene GH1 and cancer.